Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 10
1987 35
1988 36
1989 54
1990 108
1991 105
1992 138
1993 147
1994 189
1995 190
1996 242
1997 290
1998 261
1999 310
2000 411
2001 441
2002 498
2003 529
2004 640
2005 702
2006 758
2007 878
2008 834
2009 1063
2010 1301
2011 1463
2012 1559
2013 1688
2014 1822
2015 2120
2016 2009
2017 2103
2018 2094
2019 1009
2020 23
Text availability
Article attribute
Article type
Publication date

Search Results

23,394 results
Results by year
Filters applied: . Clear all
Page 1
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC.
Rolfo C, et al. J Thorac Oncol 2018 - Review. PMID 29885479 Free article.
The isolation and analysis of circulating cell-free tumor DNA in plasma is a powerful tool with considerable potential to improve clinical outcomes across multiple cancer types, including NSCLC. ...A multidisciplinary panel of experts in the field of thoracic oncology with interest and expertise in liquid biopsy and molecular pathology was convened by the International Association for the Study of Lung Cancer to evaluate current available evidence with the aim of producing a set of recommendations for the use of liquid biopsy for molecular analysis in guiding the clinical management of advanced NSCLC patients as well as identifying unmet needs. ...
The isolation and analysis of circulating cell-free tumor DNA in plasma is a powerful tool with considerable potential to improve cli …
Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint.
Hellmann MD, et al. Lancet Oncol 2014 - Review. PMID 24384493 Free PMC article.
Improvements in outcomes for patients with resectable lung cancers have plateaued. Clinical trials of resectable non-small-cell lung cancers with overall survival as the primary endpoint require a decade or longer to complete, are expensive, and limit innovation. ...We support the incorporation of major pathological response as a surrogate endpoint for survival in future neoadjuvant trials of resectable lung cancers. ...
Improvements in outcomes for patients with resectable lung cancers have plateaued. Clinical trials of resectable non-small
The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer.
Bremnes RM, et al. J Thorac Oncol 2011 - Review. PMID 21107292 Free article.
Stromal changes at the invasion front include the appearance of carcinoma-associated fibroblasts (CAFs). CAFs constitute a major portion of the reactive tumor stroma and play a crucial role in tumor progression. ...Furthermore, it presents recent literature on relevant tumor stroma- and CAF-related research in non-small cell lung cancer....
Stromal changes at the invasion front include the appearance of carcinoma-associated fibroblasts (CAFs). CAFs constitute a major port …
Circulating and Tumor Myeloid-derived Suppressor Cells in Resectable Non-Small Cell Lung Cancer.
Yamauchi Y, et al. Am J Respir Crit Care Med 2018. PMID 29617574
However, the characteristics of MDSCs in lung cancer are poorly understood. OBJECTIVES: We prospectively investigated MDSCs and inflammatory factors in tumor and peripheral blood samples from patients with resectable non-small cell lung cancer and studied their correlations with the disease prognosis. ...MEASUREMENTS AND MAIN RESULTS: A significant increase in the frequency of circulating monocytic (M)-MDSCs was observed in the patients with non-small cell lung cancer compared with the healthy donors (HDs). ...
However, the characteristics of MDSCs in lung cancer are poorly understood. OBJECTIVES: We prospectively investigated MDSCs and infla …
Precision Medicine in Non-Small Cell Lung Cancer: Current Standards in Pathology and Biomarker Interpretation.
Brown NA, et al. Am Soc Clin Oncol Educ Book 2018 - Review. PMID 30231309 Free article.
Non-small cell lung cancer (NSCLC) has become a prominent example of precision medicine among solid tumor malignancies. Clinical management of NSCLC now depends on surgical, chemotherapeutic, and radiation treatment regimens based on pathologic findings and clinical staging as well as targeted therapies based on molecular profiling. As molecular testing becomes increasingly important, preserving tissue for this purpose while rendering an accurate histologic diagnosis becomes a key consideration, particularly in advanced-stage NSCLC, in which small biopsy samples or aspirates are often the only specimen available. ...
Non-small cell lung cancer (NSCLC) has become a prominent example of precision medicine among solid tumor malign
Progress in the Management of Early-Stage Non-Small Cell Lung Cancer in 2017.
Donington JS, et al. J Thorac Oncol 2018 - Review. PMID 29654928 Free article.
The landscape of care for early-stage non-small cell lung cancer continues to evolve. While some of the developments do not seem as dramatic as what has occurred in advanced disease in recent years, there is a continuous improvement in our ability to diagnose disease earlier and more accurately. ...Experts in the care of early-stage lung cancer patients have provided focused updates across multiple areas including screening, pathology, staging, surgical techniques and novel technologies, adjuvant therapy, radiotherapy, surveillance, disparities, and quality of life. ...
The landscape of care for early-stage non-small cell lung cancer continues to evolve. While some of the developm …
The Optimal Treatment for Stage IIIA-N2 Non-Small Cell Lung Cancer: A Network Meta-Analysis.
Zhao Y, et al. Ann Thorac Surg 2019. PMID 30557543
BACKGROUND: The optimal treatment for stage IIIA-N2 non-small cell lung cancer (NSCLC) is controversial. We aimed to address this important issue through a Bayesian network meta-analysis. ...
BACKGROUND: The optimal treatment for stage IIIA-N2 non-small cell lung cancer (NSCLC) is controversial. We aime …
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
Masters GA, et al. J Clin Oncol 2015. PMID 26324367 Free PMC article.
PURPOSE: To provide evidence-based recommendations to update the American Society of Clinical Oncology guideline on systemic therapy for stage IV non-small-cell lung cancer (NSCLC). ...In the second-line setting, recommendations include docetaxel, erlotinib, gefitinib, or pemetrexed for patients with nonsquamous cell carcinoma; docetaxel, erlotinib, or gefitinib for those with squamous cell carcinoma; and chemotherapy or ceritinib for those with ALK rearrangement who experience progression after crizotinib. ...
PURPOSE: To provide evidence-based recommendations to update the American Society of Clinical Oncology guideline on systemic therapy for sta …
[PROGNOSTIC FACTORS IN NON SMALL CELL LUNG CANCER].
Gester F, et al. Rev Med Liege 2016 - Review. PMID 26983312 French. Free article.
Non small cell lung cancer is the most frequent type of lung cancer and its prognosis is still very poor. Relapse is frequent and can be observed even in early stages of the disease, in spite of a surgical management with curative intent. ...
Non small cell lung cancer is the most frequent type of lung cancer and its prognosis is still very poor.
Sequencing Therapy for Genetically Defined Subgroups of Non-Small Cell Lung Cancer.
Yu HA, et al. Am Soc Clin Oncol Educ Book 2018 - Review. PMID 30231382 Free article.
The practice of precision medicine for patients with metastatic non-small cell lung cancer (NSCLC), particularly those patients with adenocarcinoma histology (the predominant subtype of NSCLC), has become the accepted standard of care worldwide. ...We focus on established targets, including EGFR, anaplastic lymphoma kinase (ALK), ROS1, BRAF, RET, MET, HER2, and neurotrophic tyrosine kinase receptor (NTRK), with a particular emphasis on the sequencing of small molecule inhibitors in these genetically defined cohorts of patients with lung cancer....
The practice of precision medicine for patients with metastatic non-small cell lung cancer (NSCLC), particularly …
23,394 results
Jump to page
Feedback